[HT-03] Newly Emerging Concepts on PSP and CBD

[HT-03-2] Early pathological changes of CBD

Helen Ling (Queen Square Brain Bank, Institute of Neurology, University College London, UK)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

Helen is a neurologist with a special interest in movement disorders. Her main research interest is clinico-pathological correlations in tauopathies including corticobasal degeneraiton, progressive supranuclear palsy and chronic traumatic encephalopathy. She is well-published in these topics with multiple first-authored publications in high impact journals such as Brain and Acta Neuropathologica. Helen is currently funded by CBD Solutions to study the pathological progression of CBD at Queen Square Brain Bank. Helen was awarded the prestigious Junior Award for Excellence in Clinical Research by the International Movement Disorders Society and the Charles Symonds Prize by the Association of British Neurologists.

Published articles:
http://www.ncbi.nlm.nih.gov/pubmed/?term=helen+ling